CO2-Patterns During Hyperoxia and Physical Exercise in COPD
CO2-Patterns During Hyperoxia and Physical Exercise in People With Severe COPD - a Randomized, Double-blind Cross Over Trial
Aperçu de l'étude
Statut
Les conditions
Intervention / Traitement
Description détaillée
Rationale:
Carbon dioxide partial pressure (PCO2) varies significantly in patients with advanced chronic obstructive pulmonary disease (COPD). Data from the Swedish LTOT Registry showed that PCO2 is an independent predictor for mortality and that there is a U-shaped relationship. Patients with advanced COPD who are still normocapnic at rest may still develop a clinically relevant, exercise-induced carbon dioxide (CO2) retention during exercise/ activity. It is also known that altered breathing patterns at night in COPD patients can lead to nocturnal hypercapnia, especially during REM sleep. The course of PCO2 cannot be reliably predicted by lung function parameters or resting blood gas analysis. Since exercise tests with blood gas control or nightly PCO2 monitoring are rarely performed in clinical routine, exercise induced CO2 retention often remains undetected. In the literature, there is little information on PCO2 behaviour under everyday conditions (with or without LTOT) such as rest, physical exertion and nightly sleep. Therefore, predictors that could describe the PCO2 patterns are missing. However, one former study by O'Donnel from 2002 showed that the change in CO2 under hyperoxia conditions could provide predictive information for the change in CO2 with exercise.
Objective:
Primary aim of this study is to investigate whether the change of PCO2 during a hyperoxia-test (10l/min O2 at rest) correlates with the change of PCO2 during walking exercise with either a: l/min O2 as prescribed; b: medical air; c: 10l/min O2.
Design:
This study is a randomized, controlled cross-over trial. Following an initial maximal incremental shuttle walk test (ISWT), the participant will perform 3 endurance shuttle walk tests (ESWT) at 85% of the maximum ISWT pace on three consecutive days (24h break between ESWTs). In a randomized order, participants will perform one ESWTs with O2-flow as prescribed (e.g. study day 1), one with medical air (same flow rate as prescribed oxygen) (e.g. study day 2) and one with 10l/min O2 (e.g. study day 3). An additional hyperoxia test (10l/min O2 for ten minutes; at resting condition) will be perfomed on each day prior to performing an ESWT.
Type d'étude
Inscription (Anticipé)
Phase
- N'est pas applicable
Contacts et emplacements
Coordonnées de l'étude
- Nom: Tessa Schneeberger
- Numéro de téléphone: +498652931540 +498652931540
- E-mail: TSchneeberger@Schoen-Klinik.de
Lieux d'étude
-
-
-
Schönau am Königssee, Allemagne, 83471
- Recrutement
- Klinikum Berchtesgadener Land, Schön Kliniken
-
Contact:
- Tessa Schneeberger, MSc
- Numéro de téléphone: 0049 - 8652 - 932730
- E-mail: tschneeberger@schoen-klinik.de
-
-
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
- Enfant
- Adulte
- Adulte plus âgé
Accepte les volontaires sains
Sexes éligibles pour l'étude
La description
Inclusion Criteria:
- COPD III/ IV
- 35mmHg < PCO2 <= 55mmHg (under resting conditions, breathing room air)
- Hypoxemia (PaO2<60mmHg) under room air conditions (rest or during exercise) or SpO2 <88% during exercise
- established oxygen therapy or given indication for oxygen therapy
- written informed consent
Exclusion Criteria:
- acute exacerbation of COPD
- exercise limiting cardiac or orthopedic comorbidites
- PaO2 <50mmHg at rest, breathing room air
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
- Objectif principal: Traitement
- Répartition: Randomisé
- Modèle interventionnel: Affectation croisée
- Masquage: Double
Armes et Interventions
Groupe de participants / Bras |
Intervention / Traitement |
|---|---|
|
Expérimental: Randomised to begin with oxygen-supplementation at 10L/min during ESWT
Randomised order of tests starting with the 10L/min O2, during the ESWT followed by prescribed O2 flow rate or medical air in randomised order on seperate days
|
Supplemental O2 at rest of 10 l/min for ten minutes followed by supplemental O2 at the prescribed exercise O2-flow rate during ESWT.
Supplemental O2 at rest of 10 l/min for ten minutes followed by medical Air at prescribed O2 flow rate during ESWT.
Supplemental O2 at rest of 10 l/min for ten minutes followed by 10L/min O2 during ESWT.
|
|
Expérimental: Randomised to begin with medical air supplementation at prescibed O2 flow rate during ESWT
Randomised order of tests starting with the medical air during the ESWT followed by prescribed O2 flow rate or 10L/min O2 in randomised order on seperate days
|
Supplemental O2 at rest of 10 l/min for ten minutes followed by supplemental O2 at the prescribed exercise O2-flow rate during ESWT.
Supplemental O2 at rest of 10 l/min for ten minutes followed by medical Air at prescribed O2 flow rate during ESWT.
Supplemental O2 at rest of 10 l/min for ten minutes followed by 10L/min O2 during ESWT.
|
|
Expérimental: Randomised to begin with oxygen supplementation at prescibed O2 flow rate during ESWT
Randomised order of tests starting with the prescribed O2 flow rate, during the ESWT followed by 10L/min O2 or medical air in randomised order on seperate days
|
Supplemental O2 at rest of 10 l/min for ten minutes followed by supplemental O2 at the prescribed exercise O2-flow rate during ESWT.
Supplemental O2 at rest of 10 l/min for ten minutes followed by medical Air at prescribed O2 flow rate during ESWT.
Supplemental O2 at rest of 10 l/min for ten minutes followed by 10L/min O2 during ESWT.
|
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Change in PCO2 during hyperoxia at rest
Délai: Change from baseline to after 10 minutes breathing 10L/min oxygen
|
pCO2 measured by capillary blood gases taken before and after the hyperoxia test
|
Change from baseline to after 10 minutes breathing 10L/min oxygen
|
|
Change in PCO2 from rest to end exercise (endurance shuttle walk test)
Délai: Change from baseline to the end of the ESWT, up to 20 minutes
|
pCO2 measured by capillary blood gases taken before and after the ESWT
|
Change from baseline to the end of the ESWT, up to 20 minutes
|
Mesures de résultats secondaires
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Transcutaneous partial pressure of CO2 (TcPCO2) during hyperoxia test
Délai: Continuously from baseline to 10 minutes breathing 10L/min oxygen
|
TcPCO2 measured by continuous transcutaneous recording via Sentec-Digital Monitor® (Sentec, Therwil, Switzerland)
|
Continuously from baseline to 10 minutes breathing 10L/min oxygen
|
|
Transcutaneous partial pressure of CO2 (TcPCO2) during endurance shuttle walk test
Délai: Continuously during ESWT, up to 20 minutes
|
TcPCO2 measured by continuous transcutaneous recording via Sentec-Digital Monitor® (Sentec, Therwil, Switzerland)
|
Continuously during ESWT, up to 20 minutes
|
|
Breathing frequency during hyperoxia test
Délai: Continuously from baseline to 10 minutes breathing 10L/min oxygen
|
Breathing frequency during the hyperoxia test measured by ApneaLink Air™ (ResMed)
|
Continuously from baseline to 10 minutes breathing 10L/min oxygen
|
|
Breathing frequency during endurance shuttle walk test
Délai: Continuously during ESWT, up to 20 minutes
|
Breathing frequency during the ESWT measured by ApneaLink Air™ (ResMed)
|
Continuously during ESWT, up to 20 minutes
|
|
Heart rate during endurance shuttle walk test
Délai: Continuously during ESWT, up to 20 minutes
|
Heart rate measured by continuous transcutaneous recordung via Sentec-Digital Monitor® (Sentec, Therwil, Switzerland)
|
Continuously during ESWT, up to 20 minutes
|
|
Heart rate during hyperoxia test
Délai: Continuously from baseline to 10 minutes breathing 10L/min oxygen
|
Heart rate measured by continuous transcutaneous recordung via Sentec-Digital Monitor® (Sentec, Therwil, Switzerland)
|
Continuously from baseline to 10 minutes breathing 10L/min oxygen
|
|
Change of capillary partial pressure of O2 (pO2) during endurance shuttle walk test
Délai: Change from baseline to the end of the ESWT, up to 20 minutes
|
pO2 measured by capillary blood gases taken before and after the ESWT
|
Change from baseline to the end of the ESWT, up to 20 minutes
|
|
Change of inspiratory capacity during endurance shuttle walk test
Délai: Change from baseline to the end of the ESWT, up to 20 minutes
|
IC measured by SpiroSense (Pari) before and after the ESWT
|
Change from baseline to the end of the ESWT, up to 20 minutes
|
Collaborateurs et enquêteurs
Parrainer
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude (Réel)
Achèvement primaire (Anticipé)
Achèvement de l'étude (Anticipé)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Réel)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Mots clés
Termes MeSH pertinents supplémentaires
Autres numéros d'identification d'étude
- CO2-Hyperoxia & Exercise
Plan pour les données individuelles des participants (IPD)
Prévoyez-vous de partager les données individuelles des participants (DPI) ?
Type d'informations de prise en charge du partage d'IPD
- PROTOCOLE D'ÉTUDE
- CIF
Informations sur les médicaments et les dispositifs, documents d'étude
Étudie un produit pharmaceutique réglementé par la FDA américaine
Étudie un produit d'appareil réglementé par la FDA américaine
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .